Keep up to date
Univercells news | 05.02.2019
Univercells presents its scale-X bioreactor system for viral vectors production
Univercells presents its scale-X bioreactor system for viral vectors production with a proof of concept with HEK293 cell growth & ...
Press release | 11.01.2019
Univercells introduces breakthrough vaccine manufacturing platform
Univercells announces today the commercial launch of its proprietary NevoLine™ bioproduction system for vaccines.
In the press | 01.11.2018
Scaling up Novel Therapies
Our Product Manager Alex chatel and other peers from the industry discuss about technologies used to improve scale-up and the challenges ...
Univercells news | 10.09.2018
Univercells welcomes Pierre Morgon as member of the Board of Directors
Dr. Pierre Morgon brings his notable experience and extensive industry knowledge to reinforce Univercells’ business strategy and ...
In the press | 21.08.2018
Hugues Bultot, CEO of Univercells (French)
Le CEO d’Univercells Hugues Bultot nous explique comment il compte révolutionner la manière dont on produit les vaccins pour rendre ...
Press release | 16.07.2018
Univercells raises €16 million in Series B financing round led by Global Health Investment Fund
Investment proceeds will support commercialization of the company’s breakthrough biologics manufacturing technology
Univercells news | 09.07.2018
Univercells presents preliminary data from its Polio vaccine production platform
Data demonstrates how its micro-facility can achieve a 10-fold reduction in Polio vaccine manufacturing costs
Univercells news | 25.06.2018
Univercells appoints Christian Borgniet as Chief Operating Officer
Announcing Christian Borgniet, our new COO, bringing to the table his twenty-five years of broad industry experience and knowledge garnered ...